Thromb Haemost 2001; 85(02): 314-319
DOI: 10.1055/s-0037-1615686
Review Article
Schattauer GmbH

β2-glycoprotein I Binding to Platelet Microparticle Membrane Specifically Reduces Immunoreactivity of Glycoproteins IIb/IIIa

Laurent Vallar
1   Laboratoire Franco-Luxembourgeois de Recherche Biomédicale (CNRS and CRP-Santé), Centre Universitaire, Luxembourg
,
Véronique Regnault
2   Laboratoire d’Hématologie, UMR CNRS 7563, Faculté de Médecine, Vandoeuvre-lès-Nancy, France
,
Véronique Latger-Cannard
2   Laboratoire d’Hématologie, UMR CNRS 7563, Faculté de Médecine, Vandoeuvre-lès-Nancy, France
3   Hématologie Biologique, CHU, Nancy, France
,
Thomas Lecompte
2   Laboratoire d’Hématologie, UMR CNRS 7563, Faculté de Médecine, Vandoeuvre-lès-Nancy, France
3   Hématologie Biologique, CHU, Nancy, France
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Received 22. Februar 2000

Accepted after resubmission 25. September 2000

Publikationsdatum:
08. Dezember 2017 (online)

Summary

We have investigated β2-glycoprotein I (β2GPI) binding to platelet-derived microparticles (PMP) and its effect on GPIIb/IIIa. PMP were isolated from washed human platelets after stimulation with A23187, and analyzed by surface plasmon resonance spectroscopy. β2GPI as well as activated protein C (APC) or annexin V bound to PMP-coated sensorchips, demonstrating exposure of anionic phospholipids on immobilized PMP. β2GPI binding was impaired by calcium and occurred in a concentration-dependent manner with apparent kon = 2.6104 M-1.s-1 and koff = 4.410-3 s-1, corresponding to a KD value of 1.710-7 M. When analyzed by flow cytometry, the binding of certain mAbs specific for GPIIb and/or GPIIIa was reduced in the presence of β2GPI but not of APC or annexin V, whereas the binding of anti-GPIb or anti-P-selectin mAbs, or of soluble fibrinogen remained unchanged. These results suggest a broad but specific influence of β2GPI on GPIIb/IIIa immunoreactivity, and indicate that β2GPI may act as a modulator of GPIIb/IIIa-dependent functions of PMP.

 
  • References

  • 1 Hunt JE, Simpson RJ, Krillis SA. Identification of a region of beta 2-glyco-protein I critical for lipid binding and anti-cardiolipin antibody cofactor activity. Proc Natl Acad Sci USA 1993; 90: 2141-5.
  • 2 Shi W, Chong BH, Chesterman CN. β2-glycoprotein I is a requirement for anticardiolipin antibodies binding to activated platelets: differences with lupus anticoagulants. Blood 1993; 81: 1255-62.
  • 3 Schousboe I. β2-glycoprotein I: a plasma inhibitor of the contact activation of the intrinsic blood coagulation pathway. Blood 1985; 66: 1086-91.
  • 4 Nimpf J, Bevers EM, Bomans PHH, Till U, Wurm H, Kostner GM, Zwaal RFA. Prothrombinase activity of human platelets is inhibited by β2-glyco-protein-I. Biochim Biophys Acta 1986; 884: 142-9.
  • 5 Shi W, Chong BH, Hogg PJ, Chesterman CN. Anticardiolipin antibodies block the inhibition by β2-glycoprotein I of the factor Xa generating activity of platelets. Thromb Haemost 1993; 70: 342-5.
  • 6 Nomura S, Fukuhara S, Komiyama Y, Takahashi H, Matsuura E, Nakagaki T, Funatsu A, Sugo T, Matsuda M, Koike T. β2-glycoprotein I and anticardiolipin antibody influence factor Xa generation but not factor Xa binding to platelet-derived microparticles. Thromb Haemost 1994; 71: 526-7.
  • 7 Nimpf J, Wurm H, Kostner GM. Interaction of β2-glycoprotein-I with human blood platelets: influence upon the ADP-induced aggregation. Thromb Haemost 1985; 54: 397-401.
  • 8 Chang CP, Zhao J, Wiedmer T, Sims PJ. Contribution of platelet microparticle formation and granule secretion to the transmembrane migration of phosphatidylserine. J Biol Chem 1993; 268: 7171-8.
  • 9 Thiagarajan P, Tait JF. Binding of annexin V/placental anticoagulant protein I to platelets. Evidence for phosphatidylserine exposure in the procoagulant response of activated platelets. J Biol Chem 1990; 265: 17420-3.
  • 10 George JN, Pickett EB, Saucerman S, McEver RP, Kunicki TJ, Kieffer N, Newman PJ. Platelet surface glycoproteins. Studies on resting and activated platelets and platelet membrane microparticles in normal subjects and observations in patients during adult respiratory distress syndrome and cardiac surgery. J Clin Invest 1986; 78: 340-8.
  • 11 Fox JEB, Austin CD, Boyles JK, Steffen K. Role of the membrane skeleton in preventing the shedding of procoagulant-rich microvesicles from the platelet plasma membrane. J Cell Biol 1990; 111: 483-93.
  • 12 Wiedmer T, Shattil SJ, Cunningham M, Sims PJ. Role of calcium and cal-pain in complement-induced vesiculation of the platelet plasma membrane and in the exposure of the platelet factor Va receptor. Biochemistry 1990; 29: 623-32.
  • 13 Holme PA, Solum NO, Brosstad F, Pedersen T, Kveine M. Microvesicles bind soluble fibrinogen, adhere to immobilized fibrinogen and coaggregate with platelets. Thromb Haemost 1998; 79: 389-94.
  • 14 Gilbert GE, Sims PJ, Wiedmer T, Furie B, Furie BC, Shattil SJ. Platelet-derived microparticles express high affinity receptors for factor VIII. J Biol Chem 1991; 266: 17261-8.
  • 15 Regnault V, De Maistre E, Geschier C, Briquel ME, Andre E, Stoltz JF, Lecompte T. A new fast one-step immunopreparation for activated protein C. Thromb Haemost 1995; 73: 1365.
  • 16 Regnault V, Arvieux J, Vallar L, Lecompte T. Immunopurification of human β2-glycoprotein I with a monoclonal antibody selected for its binding kinetics using a surface plasmon resonance biosensor. J Immunol Methods 1998; 211: 191-7.
  • 17 Mustard JF, Perry DW, Ardlie NG, Packham MA. Preparation of suspensions of washed platelets from humans. Br J Haematol 1972; 22: 193-204.
  • 18 Barry OP, Pratico D, Lawson JA, Fitzgerald GA. Transcellular activation of platelets and endothelial cells by bioactive lipids in platelet microparticles. J Clin Invest 1997; 99: 2118-27.
  • 19 Galli M, Bevers EM, Comfurius P, Barbui T, Zwaal RFA. Effect of anti-phospholipid antibodies on procoagulant activity of activated platelets and platelet-derived microvesicles. Br J Haematol 1993; 83: 466-72.
  • 20 Wurm H. Beta-2-glycoprotein-I (apolipoprotein H) interactions with phospholipid vesicles. Int J. Biochem 1984; 16: 511-5.
  • 21 Hagihara Y, Goto Y, Kato H, Yoshimura T. Role of N- and C-terminal domains of bovine beta 2-glycoprotein I in its interaction with cardiolipin. J Biochem (Tokyo) 1995; 118: 129-36.
  • 22 Willems GM, Janssen MP, Pelsers MMAL, Comfurius P, Galli M, Zwaal RFA, Bevers EM. Role of divalency in the high-affinity binding of anti-cardiolipin antibody – β2-glycoprotein I complexes to lipid membranes. Biochemistry 1996; 35: 13833-42.
  • 23 Harper MF, Hayes PM, Lentz BR, Roubey RAS. Characterization of β2-glycoprotein I binding to phospholipid membranes. Thromb Haemost 1998; 80: 610-4.
  • 24 Tait JF, Gibson D, Fujikawa K. Phospholipid binding properties of human placental anticoagulant protein-I, a member of the lipocortin family. J Biol Chem 1989; 264: 7944-9.
  • 25 Merten M, Pakala R, Thiagarajan P, Benedict CR. Platelet microparticles promote platelet interactions with subendothelial matrix in a glycoprotein IIb/IIIa-dependent mechanism. Circulation 1999; 99: 2577-82.
  • 26 Nishioka J, Ning M, Hayashi T, Suzuki K, Protein C. inhibitor secreted from activated platelets efficiently inhibits activated protein C on phosphatidylethanolamine of platelet membrane and microvesicles. J Biol Chem 1998; 213: 11281-7.
  • 27 Horstman LL, Ahn YS. Platelet microparticles: a wide-angle perspective. Crit Rev Oncol Hematol 1999; 30: 111-42.
  • 28 Tans G, Rosing J, Thomassen MC, Heeb MJ, Zwaal RF, Griffin JH. Comparison of anticoagulant and procoagulant activities of stimulated platelets and platelet-derived microparticles. Blood, 1991; 77: 2641-8.
  • 29 Barry OP, Fitzgerald GA. Mechanisms of cellular activation by platelet microparticles. Thromb Haemost 1999; 82: 794-800.
  • 30 Byzova TV, Plow EF. Networking in the hemostatic system. Integrin αIIbβ3 binds prothrombin and influences its activation. J Biol Chem 1997; 272: 27183-8.